Şunu aradınız:: manifested (İngilizce - Maltaca)

overdose may be manifested by nausea and vomiting.
doża eċċessiva tista 'timmanifesta bħala tqalligħ u rimettar.

this was manifested as mortality and reduced foetal weight.
dan intwera bħala mortalità u piż tal-fetu mnaqqas.

sufentanil overdose is manifested by an exaggeration of its pharmacological effects.
doża eċċessiva ta’ sufentanil hija evidenzjata minn eżaġerazzjoni tal-effetti farmakoloġiċi tagħha.

hallucination effect on the kidney manifested by swelling of the extremities and weight gain
alluċinazzjoni effett fuq il-kliewi li jintwera permezz ta’ nefħa fl-estremitajiet u żieda fil-piż

arachnoiditis is a syndrome manifested primarily by nausea, vomiting, headache and fever.
l-araknojdite hi sindrome li tintwera primarjament permezz tad-dardir, rimettar, uġigħ ta’ ras u deni.

myelosuppression is dose dependent and primarily manifested as neutropenia (section 4.8).
il-majelosoppressjoni tiddependi fuq id-doża u tidher primarjament bħala newtropenija (sezzjoni 4.8).

anticipated complications of overdose include bone marrow suppression as manifested by neutropenia, thrombocytopenia and anaemia.
komplikazzjonijiet mistennija ta’ doża eċċessiva jinkludu: soppressjoni tal-mudullun kif jixhdu n-newtropenja, t-tromboċitopenja u l-anemija.

the antihypertensive effect is largely manifested within 1 week and the maximum effect is generally seen within 4 weeks.
l-effett kontra l-pressjoni għolja jidher l-aktar fi żmien ġimgħa u l-akbar effett ġeneralment jidher fi żmien 4 ġimgħat.

arachnoiditis, a very common adverse reaction associated with depocyte, is a syndrome manifested by several adverse reactions.
l-araknojdite, reazzjoni avversa komuni ħafna assoċjata ma’ depocyte, huwa sindromu b’diversi reazzjonijiet avversi.

in this study, fluid retention was manifested by early weight gain, decreased haemoglobin concentration and increased incidence of leg oedema.
f’dan l-istudju, iż-żamma tal-fluwidu ntweriet f’żieda fil-piż tal-pazjent fil-bidu tal-kura, tnaqqis fil-konċentrazzjoni ta’ l-emoglobina u żieda fl-inċidenza ta’ edima fis-saqajn.

local anaesthetic toxicity is manifested by symptoms of nervous system excitation and, in severe cases, central nervous and cardiovascular depression.
it-tossiċità tal-anestetiku lokali hija mmanifestata mis-sintomi ta’ eċċitazzjoni tas-sistema nervuża u, f’każijiet severi, depressjoni kardjovaskulari u tas-sistema nervuża ċentrali.

teratogenicity was observed in rats at doses ≥ 0.2 mg/kg and was manifested by external, visceral and skeletal malformations.
teratoġeniċità dehret f’firien b’dożi ≥ 0.2 mg/kg u ħarġet bħala malformazzjonijiet esterni, vixxerali u skeletriċi.

allergic type reactions include anaphylaxis and have been manifested by dizziness, paresthesias, rash, flushing, face swelling, urticaria, and pruritus.
reazzjonijiet tat-tip allerġiku jinkludu anafilassi u dehru permezz ta’ sturdament, parestesiji, raxx, fwawar, nefħa fil-wiċċ, urtikarja, u ħakk.

the most commonly reported adverse reactions related to halaven, are bone marrow suppression manifested as neutropenia, leucopenia, anaemia, thrombocytopenia with associated infections.
ir-reazzjonijiet avversi li kienu rrappurtati b’mod l-aktar komuni relatati ma’ halaven, huma soppressjoni tal-mudullun li tidher bħala newtropenija, lewkopenija, anemija, tromboċitopenija b’infezzjonijiet assoċjati.

with ryzodeg, hypersensitivity (manifested with swelling of tongue and lips, diarrhoea, nausea, tiredness and itching) and urticaria were reported rarely.
b'ryzodeg, reazzjonijiet ta' sensittività eċċessiva (li turi ruħha permezz ta' nefħa fl-ilsien u fix- xofftejn, dijarea, nawsja, għeja u ħakk) u urtikarja, ġew irrappurtati b'mod rari.

pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia and anaemia (or pancytopenia) (see section 4.8).
pemetrexed jista’ jissopprimi l-funzjoni tal-mudullun kif manifestat min-newtropenja, mit- tromboċitopenja u mill-anemija (jew panċitopenja) (ara sezzjoni 4.8).

pemetrexed can suppress bone marrow function as manifested by neutropenia, thrombocytopenia, and anaemia (or pancytopenia) (see section 4.8).
pemetrexed jista’ jissopprimi l-funzjoni tal-mudullun kif manifestat min-newtropenja, tromboċitopenja u anemija (jew panċitopenja) (ara sezzjoni 4.8).

bone marrow suppression manifested as neutropenia, anaemia, thrombocytopenia, or pancytopenia may occur (see “risk of neutropenia” and “anaemia” in section 4.4 below).
jista’ jkun hemm soppressjoni tal-mudullun li tidher bħala newtropenija,anemija, tromboċitopenija jew panċitopenija (ara “riskju ta’ newtropenija” u “anemija” f’sezzjoni 4.4 aktar ’l isfel).